National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

Featured Clinical Trials

Cancer Studies Highlighted in the NCI Cancer Bulletin

Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Search by Cancer Type
Breast Cancer

Colon and Rectal Cancer

Lung Cancer

Prostate Cancer

More Featured Trials
Search Featured Trials

    Search  
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Colorectal Cancer Drugs Require Careful Patient Selection

Cetuximab for Advanced Lung Cancer

Past Highlights
You CAN Quit Smoking Now!
Related Pages
Clinical Trial Search
NCI's PDQ® registry of cancer clinical trials.

Learning About Clinical Trials
What clinical trials are, how they work, and other educational materials for patients and professionals.

NCI Cancer Bulletin
A weekly newsletter produced by the National Cancer Institute.
Featured Clinical Trials Supported by the National Cancer Institute

Today, hundreds of cancer clinical trials are under way in the United States. Clinical trials answer vital research questions that lead to better screening, prevention, diagnosis, and treatment options for all cancers. This section highlights NCI-supported cancer trials featured in the NCI Cancer Bulletin and demonstrates the breadth of clinical cancer research supported by the NCI.

To find other cancer trials open to enrollment:

  • Call the National Cancer Institute’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237) for information about trials all across the country. The call is toll-free and completely confidential.
  • Use the basic PDQ search form to look online for trials listed in NCI's clinical trials database. The top of the form has a Help link for tips about searching for clinical trials.
  • For information about cancer trials taking place on the National Institutes of Health campus in Bethesda, Maryland, call the National Cancer Institute’s Clinical Studies Support Center at 1-888-NCI-1937 (1-888-624-1937). The call is toll-free and completely confidential.
1.  Treatment for Advanced Carcinoid Tumors
(Posted: 06/24/2008) - In this trial, patients with advanced nueroendocrine carcinoid tumors that have spread (metastasized) or that cannot be surgically removed (unresectable) will be randomly assigned to receive the drug octreotide acetate along with either bevacizumab or another drug called interferon alfa.

2.  Cilengitide for PSA-Only Progressive Prostate Cancer
(Posted: 03/27/2007, Updated: 06/17/2008) - In this trial, men with prostate cancer that is progressing, as indicated by a rising PSA level, despite antiandrogen therapy will be treated with a drug called cilengitide, which blocks receptor proteins that help prostate cancer grow and spread.

3.  Preventing Mucositis in Head and Neck Cancer Patients
(Posted: 03/20/2007, Updated: 06/17/2008) - In this trial, patients undergoing combination chemotherapy and radiation therapy (chemoradiotherapy) for advanced head and neck cancer will receive intravenous palifermin or placebo before and during cancer treatment to prevent mucositis, a common but serious side effect of chemoradiotherapy for this type of cancer.

4.  Chemotherapy for Inoperable Liver Metastases from Ocular Melanoma
(Posted: 11/30/2004, Updated: 06/13/2008) - In this study, researchers are testing a procedure called hyperthermic isolated hepatic perfusion to treat inoperable liver metastases secondary to ocular melanoma.

5.  More Effective Treatment for Colorectal Metastases to the Liver
(Posted: 03/22/2005, Updated: 06/13/2008) - In this phase II study, researchers are using a surgical procedure known as isolated hepatic perfusion (IHP) to deliver melphalan, an anticancer drug, directly to the liver while avoiding unnecessary systemic toxicity.
1 2 3 4   Next >

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov